Latest News

• Request for Brain Tumor Survivor Stories        

  Patients newly diagnosed with a brain tumor often seek out stories from others who have survived and thrived despite having the same diagnosis. These stories are crucial for giving hope and motivation to patients, caregivers and families. The Musella Foundation is looking for brain tumor Survivor Stories for potential inclusion on our Survivor Stories webpage, in our Brain Tumor Guide for the Newly Diagnosed (focused on high-grade brain tumors), and/or in our forthcoming Low Grade Brain Tumor Guide (focused on low-grade brain tumors). 
  
  If you would like to share your brain tumor Survivor Story, please send an email to vanessa@virtualtrials.org.

  
  
• Systematic Review and Clinical Insights: The Role of the Ketogenic Diet in Managing Glioblastoma in Cancer Neuroscience        

  There is substantial interest in the ketogenic diet as a potential complementary approach to standard treatment for glioblastoma. While more research is needed, this recent meta-analysis provides a succinct overview of the available evidence to date.   

  
  
• Upcoming presentation at EANO on mycophenolate mofetil (MMF)        

  The annual European Association of Neuro-Oncology conference (EANO 2024) is coming up in a few weeks, and one of the presentations will share data from the Phase 0/1 study of mycophenolate mofetil (MMF) in newly diagnosed and recurrent glioblastoma (GBM). MMF inhibits an enzyme required for purine metabolism in GBM cells. The study, although small, showed effective target engagement and inhibition of purine synthesis. Interim median overall survival was 15.6 in the recurrent GBM arm of the study and was not yet reached in the newly diagnosed arm. Based on the study results, the investigators have identified a recommended dose for a future Phase 2 trial.